Most Accessed Articles

HSP90 Inhibitors: Current Development and Potential in Cancer Therapy

, 2014; 9(1): 1-20.

Katerina Sidera and Evangelia Patsavoudi


DOI: 10.2174/15748928113089990031


BET Inhibitors as Anticancer Agents: A Patent Review

, 2017; 12(4): 340-364.

Imran Ali, Gildon Choi* and Kwangho Lee*


DOI: 10.2174/1574892812666170808121228


Strategies to Tackle Radiation Resistance by Penetrating Cancer Stem Cell Line of Scrimmage

, 2018; 13(1): 18-39.

So-Yeon Park, Ji-Young Kim, Youngsoo Jun and Jeong-Seok Nam*


DOI: 10.2174/1574892812666171003150410


Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy

, 2018; 13(1): 86-105.

Marco L. Lolli, Stefano Sainas, Agnese C. Pippione, Marta Giorgis, Donatella Boschi and Franco Dosio*


DOI: 10.2174/1574892812666171108124218


Nucleic Acid Sensing Machinery: Targeting Innate Immune System for Cancer Therapy

, 2018; 13(1): 2-17.

Sandra Iurescia*, Daniela Fioretti and Monica Rinaldi*


DOI: 10.2174/1574892812666171030163804


NLRP3 Inflammasome Activation Inhibitors in Inflammation-Associated Cancer Immunotherapy: An Update on the Recent Patents

, 2018; 13(1): 106-117.

Spandana R. Kopalli , Tae-Bong Kang , Kwang-Ho Lee and Sushruta Koppula*


DOI: 10.2174/1574892812666171027102627


Pharmacological Inhibitors of NAD Biosynthesis as Potential An ticancer Agents

, 2017; 12(3): 190-207.

Stephanie Lucas, Claire Soave, Ghazal Nabil, Zainab Sabry Othman Ahmed, Guohua Chen, Hossny Awad El-Banna, Q. Ping Dou* and Jian Wang*


DOI: 10.2174/1574892812666170619125503


Adenosine Receptor Ligands on Cancer Therapy: A Review of Patent Literature

, 2018; 13(1): 40-69.

Joana B. Sousa, Paula Fresco, Carmen Diniz* and Jorge Goncalves


DOI: 10.2174/1574892812666171108115959


Activating Mutations of ESR1, BRCA1 and CYP19 Aromatase Genes Confer Tumor Response in Breast Cancers Treated with Antiestrogens

, 2017; 12(2): 136-147.

Zsuzsanna Suba*


DOI: 10.2174/1574892812666170227110842


From a Better Understanding of the Mechanisms of Action of Histone Deacetylases Inhibitors to the Progress of the Treatment of Malignant Lymphomas and Plasma Cell Myeloma

, 2017; 12(4): 283-295.

Romeo G. Mihaila*


DOI: 10.2174/1574892812666170920110054


Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science